ALBO News and Press, Albireo Pharma Inc. From 10/05/20

BOSTON, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource Network (PFIC Network) in recognition of PFIC Awareness Day 2020, a global effor...

BOSTON, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 23,000 shares of Albireo’...

Albireo reports positive data from Phase 3 trial Albireo Pharma, Inc. (ALBO) reported positive top-line data from PEDFIC 1 trial for odevixibat. The study met both its primary endpoints. The drug candidate is a highly potent, non-systemic ileal bile acid transport inhibitor. It is being ...

Albireo Pharma (NASDAQ: ALBO ) has priced its public offering of 4M common shares at $40.00/share, for expected gross proceeds of $160M. More news on: Albireo Pharma, Inc., Healthcare stocks news, , Read more ...

BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 4,000,000 shares of its comm...

BOSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it has commenced a proposed underwritten public offering of 3,000,000 shares of its common stoc...

Gainers:  Luby's (NYSE: LUB ) +102% . More news on: Luby's, Inc., Nikola Corporation, Albireo Pharma, Inc., Stocks on the move, , Read more ...

Albireo Pharma (NASDAQ: ALBO ) +82%  as odevixibat successful in late-stage study. More news on: Albireo Pharma, Inc., Nikola Corporation, Luby's, Inc., Stocks on the move, , Read more ...

Albireo Pharma (NASDAQ: ALBO ) announces positive topline results from a Phase 3 clinical trial, PEDFIC 1 , evaluating lead drug odevixibat, an ileal bile acid transporter inhibitor, in patients with a rare inherited disorder called progressive familial intrahepatic cholestasis (PFIC)...

-Highly statistically significant reductions in both pruritus and serum bile acids- -Well tolerated with very low incidence of diarrhea- -Similar efficacy in children with PFIC1 or PFIC2- -Pivotal trial results substantiate potential for odevixibat to be first drug for PFIC pa...